Search FIXX
Q32 Bio Inc.
Nasdaq · CIK 1661998
Last close14.22
Daily change+0.74 (5.49%)
10 Years gain+0.49%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
FIXX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
47.2Momentum
n/aAcceleration
n/aConfidence
64.0Annual Revenue8
Quarterly Revenue21
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Key Metrics
Revenue Growth TTM-100%OK
Revenue CAGR 3Y155.87%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $53.74M | $53.74M | $16.90M | -$33.54M | -$33.54M | 100% | 31.45% | -62.42% | n/a | 12.31M |
| 2025 FY Dec 31, 2024 | $0.00 | $0.00 | -$66.10M | -$67.72M | -$67.79M | n/a | n/a | n/a | n/a | 9.66M |
| 2024 FY Dec 31, 2023 | n/a | -$6.65M | -$48.26M | -$18.68M | -$18.68M | n/a | n/a | n/a | n/a | 349,060 |
| 2023 FY Dec 31, 2023 | $1.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| 2023 FY Dec 31, 2022 | $3.21M | $3.21M | -$133.28M | -$113.66M | -$114.95M | 100% | -4,154.64% | -3,583.1% | n/a | 57.4M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $0.00 | sum latest 4 fiscal quarters Revenue | OK | 0000950170-23-063667, 0000950170-24-056273 |
| Revenue Growth TTM | -100% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000950170-23-063667, 0000950170-24-056273 |
| Revenue CAGR 3Y | 155.87% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-099339 |
| Revenue CAGR 5Y | 81.85% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-099339 |
| Gross Profit CAGR 3Y | 155.87% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-099339 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | derived |
| Current Ratio | 6.53x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-099339 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001193125-26-099339 |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |
| Gross Margin Delta 3Y | n/a | GrossMargin_current - GrossMargin_3Y_ago | INSUFFICIENT_HISTORY | derived |